Financial Performance - The group's revenue increased by approximately RMB 173.6 million or 26.8% to approximately RMB 820.5 million compared to the year ended December 31, 2020[8]. - The group's gross profit rose by approximately RMB 102.1 million or 21.5% to approximately RMB 577.7 million compared to the year ended December 31, 2020[8]. - The group's EBITDA increased by approximately RMB 48.5 million or 20.8% to approximately RMB 281.8 million compared to the year ended December 31, 2020[8]. - The profit attributable to equity holders increased by approximately RMB 33.5 million or 21.7% to approximately RMB 187.6 million compared to the year ended December 31, 2020[8]. - The group's revenue for the year ended December 31, 2021, was approximately RMB 820.5 million, an increase of about RMB 173.6 million or 26.8% compared to RMB 646.9 million for the year ended December 31, 2020[30]. - Revenue from the sales of Jin Sangzi throat lozenges (OTC) was approximately RMB 739.2 million, up RMB 157.4 million or 27.1% from RMB 581.8 million in the previous year, indicating recovery to pre-COVID-19 levels[30]. - The sales revenue from Jin Sangzi throat treasure series products was approximately RMB 71.7 million, an increase of RMB 18.0 million or 33.5% compared to RMB 53.7 million in the previous year[31]. - The group's gross profit for the year ended December 31, 2021, was approximately RMB 577.7 million, an increase of RMB 102.1 million or 21.5% from RMB 475.6 million in the previous year[35]. - The net profit for the year ended December 31, 2021, was approximately RMB 187.6 million, an increase of about RMB 33.5 million or 21.7% compared to RMB 154.1 million for the year ended December 31, 2020[42]. - The total comprehensive income for the year was RMB 181,363 thousand, compared to RMB 143,282 thousand in 2020, marking a growth of 26.6%[166]. Dividends and Shareholder Returns - The company plans to pay a final dividend of HKD 0.18 per share for the year ended December 31, 2021, subject to shareholder approval[8]. - The company reported a final dividend of HKD 0.18 per share for the year ended December 31, 2021, subject to shareholder approval at the annual general meeting on May 13, 2022[62]. - The company maintains a stable dividend policy, prioritizing consistent cash dividend distribution as a key profit allocation goal[65]. - The company declared dividends of RMB 36,562,000 for the year, a decrease from RMB 77,069,000 in the previous year, representing a reduction of about 52.5%[170]. Research and Development - The new pharmaceutical production and R&D base has been completed with a total area of approximately 60,000 square meters, including R&D center, production plant, warehouse, and administrative office[10]. - A new land parcel of 48 acres has been selected for the second phase of the new base, expected to have a construction area of approximately 50,000 square meters for food production and R&D center[10]. - The company aims to develop new products such as gene drugs, traditional Chinese medicine formulas, and specialty health foods through its new R&D platforms[10]. - The company plans to continue optimizing its product system and enhancing organizational capabilities in 2022, focusing on consumer demand and digital marketing[19]. - The company will enhance its production capacity, expand its product portfolio, and strengthen R&D capabilities to promote synergy among different product segments[48]. Market Position and Brand Recognition - The company has been recognized as the top brand in the "Traditional Chinese Medicine - Throat Category" in the 2021 statistics of non-prescription drug enterprises and products in China[9]. - The company is focused on achieving breakthroughs in the pharmaceutical and fast-moving consumer goods sectors in 2022[11]. - The company is a leading manufacturer of throat lozenges in China, ranking first in the "Traditional Chinese Medicine - Throat Category" in 2021[18]. - The company aims to strengthen its leading position in the throat lozenge market and expand its market share in the pharmaceutical and food sectors in China[48]. Operational Challenges and Responses - The company actively responded to the COVID-19 pandemic by resuming production and donating anti-epidemic materials[18]. - In 2020, the company faced challenges due to the pandemic, with a decline in offline sales channels such as pharmacies and supermarkets[18]. - The sales situation has recovered to pre-COVID-19 levels as of 2021, despite ongoing pandemic challenges[25]. - In 2021, the company achieved a recovery in sales to pre-COVID-19 levels, supported by the overall stabilization of the pandemic situation in China[19]. Financial Position and Assets - As of December 31, 2021, the company's current assets net value was approximately RMB 855.7 million, compared to RMB 696.4 million as of December 31, 2020[43]. - Total interest-bearing bank and other borrowings as of December 31, 2021, amounted to approximately RMB 235.0 million, an increase of RMB 82.5 million compared to RMB 152.5 million as of December 31, 2020[43]. - The company's asset-liability ratio increased from approximately 12.5% as of December 31, 2020, to approximately 17.2% as of December 31, 2021[43]. - The company reported a significant increase in inventory, which rose to RMB 64,963 thousand from RMB 38,843 thousand in 2020, a growth of 67%[167]. - The total equity as of December 31, 2021, was RMB 1,365,143 thousand, compared to RMB 1,220,342 thousand in 2020, reflecting an increase of 11.9%[168]. Governance and Management - The company has established a compensation committee to determine the compensation policy based on operational performance and market practices[83]. - The board of directors consists of nine members, including five executive directors, one non-executive director, and three independent non-executive directors[119]. - The company has complied with all applicable code provisions of the corporate governance code as of December 31, 2021[117]. - The independent non-executive directors have confirmed their independence according to the listing rules[119]. - The company encourages directors to seek independent professional advice at the company's expense when fulfilling their duties[129]. Compliance and Risk Management - The company has complied with all applicable laws and regulations, with no significant violations reported as of December 31, 2021[152]. - The company has established appropriate arrangements for employees to raise concerns regarding financial reporting and internal controls[138]. - The audit committee reviewed the effectiveness of the risk management and internal control systems and deemed them effective and adequate for the year ended December 31, 2021[142]. - The company has not purchased insurance for its directors against legal actions, believing that regular communication with management can effectively handle potential claims[141]. Future Outlook and Strategic Plans - The company aims to establish a new growth logic for its products to ensure healthy development in the future[19]. - The company plans to allocate approximately HKD 189.98 million (about 21% of the IPO proceeds) for transforming its headquarters into a food production plant and R&D center[52]. - The company intends to improve brand awareness through effective targeted marketing and continue to expand its distribution network[48]. - The company has not utilized any IPO proceeds for the establishment of the traditional Chinese medicine processing base as of December 31, 2021[52].
金嗓子(06896) - 2021 - 年度财报